Jointly founded in 2023 with scientists from Max Delbrück Center for Molecular Medicine in the Helmholtz Association.
TRYPTO Therapeutics is developing a new class of tryptophan hydroxylase inhibitors to address the unmet medical need in serotonin-dependent diseases. Overproduction of serotonin in the periphery, catalysed by the enzyme tryptophan hydroxylase 1, is a key factor in the development of many chronic and life-threatening diseases, including pulmonary arterial hypertension, carcinoid syndrome, colorectal cancer and fibrosis. TRYPTO is developing innovative TPH inhibitors with nanomolar potency in vitro to reduce pathologically high serotonin synthesis in the periphery. The new generation of inhibitors differs in its scaffold, binding mode and potency from the two TPH inhibitors currently on the market or in clinical trials.
Jointly founded with scientists from Universität zu Köln in 2020.
ProSion offers a platform of breakthrough pharmaceutical building blocks, called ProMs. ProMs work like “LEGO bricks” and can be combined into lead compounds targeting proteins, linked with hard-to-treat diseases that currently cannot be addressed with existing pharmaceutical methods. With a focus on proline-rich-motif-binding domains (PRMs), the company´s platform offers new paths for drugging the undruggable.
Jointly founded with scientists from Ludwig-Maximilians Universität München in 2019.
Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Tubulis® goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. The company will advance a range of conjugates, unlimited by indication, using their own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.
In 2000, two companies have been founded by FMP researchers:
Area of expertise: structural genomics and target discovery
The company provided service in the field of lead structure optimisation, structural characterisation and validation of target proteins as well as production of recombinant proteins.
Area of expertise: combinatorial biosynthesis of natural compound libraries, pre-clinical development of antibiotic compounds
In August 2006, Combinature Biopharm AG was acquired by MerLion Pharmaceuticals Pte Ltd (MerLion) of Singapore, the world’s leading natural products based drug discovery company. MerLion’s headquarters and drug discovery research centre is based in Singapore, drug development of its anti-infective programmes and nuclear magnetic resonance screening activities are being conducted from Berlin.
In June 2007, Evotec AG acquired the NMR Fragment-Based Drug Discovery Business from MerLion Pharmaceuticals' subsidiary, Combinature Biopharm AG.